Obesity and Weight Management for Prevention and Treatment of Type 2 Diabetes

JAMA Clinical Guidelines Synopsis 

July 11, 2022

Major recommendations

  • Diet, physical activity, and behavioral therapy should be designed to achieve and maintain at least 5% weight loss. Additional weight loss usually results in further improvements in control of diabetes and cardiovascular risk (level of evidence B).

  • Interventions to achieve weight loss should include a high frequency of counseling (≥16 sessions in 6 months) to achieve a 500- to 750-kcal/d energy deficit (level of evidence A).

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial



Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.

Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19

Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro

Diabetes Care 2021 July 12

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

June 25, 2021

DOI: 10.1056/NEJMoa2107519



Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.